1998360072

AN

    1998360072  EMBASE  

TI

    Moderate intake of n-3 fatty acids for 2 months has no detrimental effect
    on glucose metabolism and could ameliorate the lipid profile in type 2
    diabetic men: Results of a controlled study.

AU

    Luo J.; Rizkalla S.W.; Vidal H.; Oppert J.-M.; Colas C.; Boussairi A.;
    Guerre- Millo M.; Chapuis A.-S.; Chevalier A.; Durand G.; Slama G.

CS

    G. Slama, Department of Diabetes, Hotel-Dieu, 1, place du Parvis
    Notre-Dame, 75181 Paris Cedex 04, France

SO

    Diabetes Care, (1998) Vol. 21, No. 5, pp. 717-724. .
    Refs: 39
    ISSN: 0149-5992  CODEN: DICAD2

CY

    United States

DT

    Journal; Article

FS

    003     Endocrinology
    029     Clinical Biochemistry
    037     Drug Literature Index

LA

    English

SL

    English

ED

    Entered STN: 19 Nov 1998
    Last Updated on STN: 19 Nov 1998

AB

    OBJECTIVE - To evaluate the effect of a moderate dose of fish oil on
    glycemic control and in vivo insulin action in type 2 diabetic men with
    elevated plasma triacylglycerols and to determine the effect of the same
    treatment on gene expression of GLUT4, lipoprotein lipase (LPL), and
    hormone- sensitive lipase (HSL) in the abdominal adipose tissue.
    RESEARCH DESIGN AND METHODS - A total of 12 type 2 diabetic men were
    randomly allocated to 2 months of 6 g daily of either fish oil or
    sunflower oil, separated by a 2- month washout interval, in a double-blind
    crossover design.  RESULTS - For glucose metabolism, 2 months of fish oil
    supplementation compared with sunflower oil led to similar fasting plasma
    insulin, glucose, and HbA(1c).  Basal hepatic glucose production did not
    increase after fish oil.  There was no difference in insulin suppression
    of hepatic glucose production nor in insulin stimulation of whole-body
    glucose disposal measured by the euglycemic-hyperinsulinemic clamp.  Fish
    oil did not ameliorate the low mRNA level of GLUT4 in adipose tissue of
    these patients.  For lipid profile, fish oil lowered plasma
    triacylglycerol more than sunflower oil (P < 0.05) and tended to increase
    the amount of mRNA of both LPL and HSL in adipose tissue.  CONCLUSIONS -
    A moderate dose of fish oil did not lead to deleterious effects on
    glycemic control or whole-body insulin sensitivity in type 2 diabetic
    men, with preserved triacylglycerol-lowering capacities.

CT

    Medical Descriptors: 
    *non insulin dependent diabetes mellitus: DT, drug therapy
    *fat intake
    glucose homeostasis
    gene expression regulation
    enzyme synthesis
    protein expression
    glucose blood level
    cholesterol blood level
    lipoprotein blood level
    triacylglycerol blood level
    insulin blood level
    human
    male
    clinical article
    clinical trial
    double blind procedure
    crossover procedure
    controlled study
    adult
    oral drug administration
    article
    Drug Descriptors: 
    *sunflower oil: CT, clinical trial
    *sunflower oil: CM, drug comparison
    *sunflower oil: DT, drug therapy
    *omega 3 fatty acid: CT, clinical trial
    *omega 3 fatty acid: CM, drug comparison
    *omega 3 fatty acid: DT, drug therapy
    *fish oil: CT, clinical trial
    *fish oil: CM, drug comparison
    *fish oil: DT, drug therapy
    glucose: EC, endogenous compound
    triacylglycerol: EC, endogenous compound
    cholesterol: EC, endogenous compound
    high density lipoprotein cholesterol: EC, endogenous compound
    lipoprotein a: EC, endogenous compound
    apolipoprotein a1: EC, endogenous compound
    insulin: EC, endogenous compound
    glucose transporter: EC, endogenous compound
    lipoprotein lipase: EC, endogenous compound

RN

    (sunflower oil) 8001-21-6; (fish oil) 8016-13-5; (glucose) 50-99-7,
    84778-64-3; (cholesterol) 57-88-5; (insulin) 9004-10-8; (lipoprotein
    lipase) 83137-80-8, 9004-02-8